OXM14

OXM14 is a synthetic peptide analogue of oxyntomodulin (OXM), an endogenous hormone that acts as a dual agonist at both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. While oxyntomodulin analogues are typically developed for the treatment of obesity and type 2 diabetes due to their ability to reduce food intake and increase energy expenditure, OXM14 was identified during screening as an analogue that paradoxically increased food intake in rat models by up to 20%. Research indicates that this orexigenic effect is mediated through glucagon receptor activation, as the effect was abolished in the Glu-3 substituted version (OXM14E3). OXM14 serves as a research tool to investigate the complex interplay between GLP-1 and glucagon signaling in appetite regulation and the pharmacology of oxyntomodulin-based therapeutics.

Other names

OXM-14OXM14OXM 14oxyntomodulin analogue 14